dc.contributor.author | Fernández-Vigo, José Ignacio | |
dc.contributor.author | Contreras, Inés | |
dc.contributor.author | Crespo, María José | |
dc.contributor.author | Beckford, Carlos | |
dc.contributor.author | Flores-Moreno, Ignacio | |
dc.contributor.author | Cobo Soriano, Rosario | |
dc.contributor.author | Pareja, Jesús | |
dc.contributor.author | Martín, María Dolores | |
dc.contributor.author | Moreno, Luis | |
dc.contributor.author | Arrevola-Velasco, Luis | |
dc.date.accessioned | 2023-04-12T10:14:45Z | |
dc.date.available | 2023-04-12T10:14:45Z | |
dc.date.issued | 2022 | |
dc.identifier.issn | 1177-5483 | spa |
dc.identifier.uri | https://hdl.handle.net/10641/3347 | |
dc.description.abstract | Purpose: The treatment of diabetic macular edema (DME) has evolved rapidly in the past decade, highlighting the need to address the
challenges of routine clinical practice decision-making through expert consensus agreements.
Methods: After a literature review and discussion of real-world experience on DME management, a group of ten retina specialists
agreed on a consensus of recommendations for the most appropriate management of DME patients using vascular endothelial growth
factor inhibitors (anti-VEGF) in Spain.
Results: The panel recommended early treatment initiation in DME patients with worse baseline visual acuity (VA) to maintain or
improve outcome. For patients with good VA, an observation strategy was recommended, considering the presence of diabetic
retinopathy, optical coherence tomography biomarkers, and impact on patient’s quality of life. Based on the available evidence and
clinical experience, the panel recommended the use of anti-VEGF intensive loading doses with the objective of achieving anatomic
and visual responses as soon as possible, followed by a Treat & Extend (T&E) strategy to maintain VA improvement. Aflibercept was
recommended for patients with a baseline decimal VA <0.5, followed by a T&E strategy, including the possibility to extend frequency
of injections up to 16 weeks.
Conclusion: An expert panel proposes a consensus for the management of DME in Spain. Early treatment initiation with anti-VEGF
in DME patients is recommended to maintain or improve VA; aflibercept is recommended for patients with a poor baseline VA. | spa |
dc.language.iso | eng | spa |
dc.publisher | Clinical Ophthalmology | spa |
dc.rights | Atribución-NoComercial-SinDerivadas 3.0 España | * |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/3.0/es/ | * |
dc.subject | Diabetic macular edema | spa |
dc.subject | Clinical practice patterns | spa |
dc.subject | Intravitreal injections | spa |
dc.title | Expert Panel Consensus for Addressing Anti-VEGF Treatment Challenges of Diabetic Macular Edema in Spain. | spa |
dc.type | journal article | spa |
dc.type.hasVersion | AM | spa |
dc.rights.accessRights | open access | spa |
dc.description.extent | 3162 KB | spa |
dc.identifier.doi | 10.2147/OPTH.S374763 | spa |
dc.relation.publisherversion | https://www.dovepress.com/expert-panel-consensus-for-addressing-anti-vegf-treatment-challenges-o-peer-reviewed-fulltext-article-OPTH | spa |